The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or
worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure
and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an
estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2 and serum potassium 5.5, >6.0, and 5.5 mmol/l but not
of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to
adverse events. Eplerenone was effective in reducing the primary composite endpoint in all subgroups.
In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria,
including an eGFR >30 ml/min/1.73 m2 and potassium